For information Telephone 919-996-0174
Man with his dog playing in the park

Reliable. Accurate. Convenient. Being proactive for your dog’s health has never been easier.

What if you could do something simple today that could help your pet before it’s too late? That’s exactly why we are developing tools to detect canine cancers earlier. Far too often, canine cancer is not detected until in its late stages, which often means less time to act to help our dogs. Our goal is to change that – one innovative product at a time. Because we believe every dog deserves a healthier future.

DiagnosticA simple free-catch urine analysis system offering the most rapid and reliable TCC/UC detection.

By offering a robust, rapid and highly sensitive diagnostic solution, veterinarians can focus on earliest detection of canine TCC/UC. This provides clinicians with the opportunity to offer their clients the most appropriate clinical management of their dogs with more time to combat the cancer sooner in the course of the disease.

TCC/UC Overview

This year, 80,000 dogs will be diagnosed with canine transitional cell carcinoma (TCC), also now known as urothelial carcinoma (UC). Using existing techniques most diagnoses are made when the cancer is at an advanced stage and has invaded the muscle wall. In 20% of cases the cancer has already spread (metastasized) to other parts of the body. These features all indicate that current diagnostic methods have very limited ability for early detection of the disease, which may in turn reduce treatment options and lead to a less favorable outcome.

TCC/UC Research

Our research at Sentinel Biomedical has shown that a single mutation in a gene called BRAF is present in 85% of confirmed cases of canine TCC/UC. With highly sensitive molecular technology, we have developed a genetic test that can detect the presence of this mutation in cells naturally shed into the urine of an affected dog. The mutation is not found in the urine of healthy dogs, or from dogs that have nonmalignant bladder polyps, inflammation or cystitis. It is therefore a highly specific indicator of the presence of a TCC/UC.

To learn more about the science behind the development of this assay click on this link to read the published study (link will open a new tab/window)


CADETSM BRAF Mutation Detection Assay

Sentinel Biomedical now offers a unique DNA-based strategy for early detection of canine TCC/UC. The CADETSM BRAF Mutation Detection Assay can detect as few as 10 mutation-bearing cells in a urine sample, several months before any clinical signs associated with the cancer become evident. This enables owners and veterinarians to initiate appropriate treatment very early in the course of the disease, potentially before the mass has become invasive. Additionally, the test allows a sensitive means to monitor affected dogs during the course of their treatment, for therapeutic response and relapse.

Unlike previous, less discriminatory tests for canine TCC/UC, the CADETSM BRAF Mutation Detection Assay is not affected by the presence of blood or bacteria in the urine. Importantly, for cases that have undergone biopsy of a visible mass, there is 100% concordance between the presence of a BRAF mutation in free-catch urine and subsequent pathology-based confirmation of a TCC/UC.

Conversely, the BRAF mutation has not been detected among hundreds of urine samples from dogs that had been diagnosed with non-malignant bladder masses or other forms of cancer. These findings demonstrate that detection of the BRAF mutation in canine urine is a highly specific indicator of the presence of a TCC/UC.

  • Accessible: Easy free-catch urine test. Simply collect urine from your dog and submit for testing from the comfort of your own home.
  • Affordable: Reduce costs associated with treating recurring symptoms, rather than the cancer itself.
  • Sensitive: Forensic-level detection, allows earliest detection and not affected by blood, protein, sugars, bacteria etc in the urine.
  • Rapid: Diagnostic/monitoring test results available in just 2-3 days. Screening test results available within 2 weeks.

Frequently Asked Questions

Transitional cell carcinoma (TCC), also known as urothelial carcinoma (UC), is the most common cancer of the canine urinary tract. TCC/UC accounts for an estimated 1-2% of all cancer cases diagnosed in dogs, with an anticipated 80,000+ diagnosed cases this year.

TCC/UC affects the bladder, urethra, and kidneys of male and female dogs and also the prostate of males. It is most often detected in the trigone of the bladder, a triangular region of smooth mucosa inside the dorsal wall of the neck of the bladder. Advancing TCC/UC often results in straining to urinate, repeated frequent attempts to urinate, blood in the urine, and bacterial infection. Thickening of the bladder wall can lead to partial or complete obstruction of urine entering the bladder from the ureters, which may lead to kidney failure.

While any breed is susceptible to developing TCC/UC, these breeds have higher than average incidence rates: American Eskimo Dog, Australian Cattle Dog, Australian Shepherd, Beagle, Bichon Frise, Border Collie, Parson Russell Terrier, Lhasa Apso, Rat Terrier, Russell Terrier, Scottish Terrier, Shetland Sheepdog, West Highland White Terrier, and Wire Fox Terrier. When combined, these breeds account for over a third of all diagnosed TCC/UC cases in purebred dogs.

Canine bladder cancer (TCC/UC) is generally a disease of mid-to- late life, with 95% of cases occurring in dogs age 6 years and older. Canine bladder cancer is rarely diagnosed until the disease is at an advanced stage. Detecting bladder cancer sooner gives dog owners and veterinarians more time to develop a treatment plan.